Phase 3
-
Merck Halts Two Phase III Clinical Trials
Drug development is not easy, and we pay tribute to the heroes of innovative drug development!
-
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
Congratulations to Alnylam and patients who may benefit from this exciting progress!
